EU Agency Calls for Restrictions on Sanofi (France)'s Multaq
Published: Sep 23, 2011
Risks of liver, cardiovascular or lung issues stemming from Sanofi's Multaq irregular heart beat drug mean its use should be restricted, Europe's drug regulator said on Thursday following a safety review. The decision could raise further pressure on Sanofi to speed up the replenishment of a drug pipeline which has been drastically diminished after a top-to-bottom review. Following a monthly meeting, the regulator's Committee on Medicinal Products for Human Use (CHMP) in London recommended the drug should only be prescribed "after alternative treatment options have been considered".